Acute Kidney Injury Treatment Market Poised for Significant Growth, Projected to Reach USD 3,566.7 Million by 2029 at a 8.2% of CAGR
The acute kidney injury treatment market is on track for substantial growth, anticipated to register a robust compound annual growth rate (CAGR) of 8.2% during the forecast period from 2022 to 2029. Starting with an estimated valuation of USD 2,058.2 million in 2022, the market is projected to exceed USD 3,566.7 million by the end of 2029.
The primary reasons for this noteworthy growth include the increasing prevalence of acute renal damage, advancements in treatment modalities, and expanding public awareness of kidney health. The development of innovative therapeutic solutions and the expanding global healthcare infrastructure are also contributing to the market’s growth trajectory.
One of the primary causes of acute kidney injury (AKI), which can be fatal, is an abrupt loss of renal function. Growing healthcare expenses, an increase in the incidence of chronic illnesses, and aging populations all contribute to the frequency of AKI. This highlights the requirement for effective therapies and fixes.
Request a report sample to gain comprehensive insights:
Key Takeaways:
- Owing to increasing acute kidney injury prevalence, number of dialysis centres, and efficient treatment method, the dialysis segment is expected to be a significant revenue generator.
- The intermittent haemodialysis segment, under product, in the acute kidney injury treatment market, is expected to be a prominent segment, as results provided by this treatment are more efficient as compared to other dialysis methods.
- The pre-renal injury segment is anticipated to dominate the acute kidney injury treatment market, as pre-renal injury is more prevalent in patients with acute kidney injury.
- North America is expected to dominate the global acute kidney injury treatment market in terms of revenue, owing to the growing adoption of advanced treatments over conventional methods. East Asia is expected to offer lucrative opportunities for the acute kidney injury treatment market during the forecast period.
Advanced Technology & Product Launches – Key Strategies Followed by Manufacturers
The participants in the acute renal injury treatment market are keeping up with advances in diagnostic technology and increased product availability in order to streamline their product offerings in respective regions with different product portfolios. For example, Fresenius Medical Care introduced the 4008A dialysis equipment in January 2022 in an effort to provide accessibility to dialysis treatment that is life-sustaining.
Customization Available:
Competitive Landscape:
To provide patients with cutting-edge care, major companies in the worldwide acute renal injury treatment market are concentrating on creating automated, mobile, and tech-driven dialysis equipment. In order to broaden their range of products, they are also using cutting-edge technology like artificial intelligence and the Internet of Things (IoT).
In the meantime, several of the other firms are developing diagnostic technologies to simplify their product offers in emerging markets where their product portfolios are diversified.
For instance:
- In March 2021, C-Path announced the launch of an acute kidney injury project in partnership with the USA Food and Drug Administration (FDA) for Drug Evaluation and Research, the Office of translational science, and the Division of cardiology and Nephrology, to develop a suite of prognostic tools to improve the detection of drug-induced kidney injury.
- In June 2021, Abionyxx announced the enrollment of the first patient in its Phase-2a clinical study with CER-001 for the treatment of septic patients at high risk of developing acute kidney injury.
Key Companies Profiled:
- Novartis, Pfizer Inc.
- Merck & Co.
- Biocon Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan Pharmaceuticals Inc.
- NIPRO Medical
- Baxter Corporation
- Asahi Kasei
- NIKKISO
- Fresenius Medical Care
- Others
Acute Kidney Injury Treatment Market By Category:
Product:
- Dialysis
- Intermittent Hemodialysis
- Continuous Renal Replacement Therapy (CRRT)
- Sustained Low-Efficiency Dialysis (SLED)
- Drug Therapy
- Antibiotics
- Diuretics
- Immunosuppressive Agents
Injury:
- Pre-renal Injury
- Intrinsic Renal Injury
- Post-renal Injury
Distribution Channel:
- Hospitals
- Ambulatory Surgical Centers
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
Gain Full to Market Insights: Purchase Now to Access:
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
link